: The Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) Is the renamed renewal of Chiang Mai University HIV/AIDS Clinical Trials Unit- Sirisanthana, Thira (Grant# U01 Al 069399, Feb 2007-Jan 2014), which expands beyond the Chiang Mai University Research Institute for Health Sciences (CMU-RIHES) to add the experience and resources of another major HIV research institution: the Thai Red Cross AIDS Research Centre (TRC-ARC), affiliated with Chulalongkorn University.
The aim of the THAI CTU Is to collaborate with five Clinical Research Networks established by NIAID, NIH under RFA-AI-12-001, -004, -008, -011, and -012, in coordinating and executing clinical research in Thailand and the neighboring region to expand knowledge and improve treatment and prevention of HIV and related Infectious diseases. It also aims to assist the CRNs In refining their research agendas to meet the needs, priorities, circumstances, and sensitivities of low- and middle-income countries in hosting research studies, so that findings are of utility fo preventing and treating HIV and related conditions both universally, as well as in the country of research. Located in the cities of Chiang Mai and Bangkok, Thailand, the THAI CTU is led by Co-Principal Investigators Suwat Chariyalertsak and Kiat Ruxrungtham, plus P. Phanuphak, T. Sirisanthana, K. Supparatpinyo, G.J.P.(F) van Griensven, V. Sirisanthan, A. Avihingsanon, T. Puthanakit, and K. Srithanaviboonchal. It is comprised of four Clinical Research Sites which will implement clinical and related HIV studies on maternal, pediatric, and adult therapeutics, on topical microbicides to prevent HIV transmission, on Integrated population-based prevention strategies, and on vaccines. After appropriate community and ethical approvals, such studies will be conducted on volunteers from populations with both high and usual risk for HIV, including those seeking voluntary counseling and testing or healthcare, men who have sex with men and transgender women, HIV-discordant couples, persons who inject drugs, pregnant, neonates, children, adolescents, blood donors, and persons from the general population.

Public Health Relevance

Enlightened prevention programs reduced HIV transmission in Thailand, a beachhead for the explosive arrival of HIV into Asia in the 1980s. However, new infections remain unacceptably frequent. Thai Institutions as RIHES and TRC-ARC provide infrastructure, population access, and indigenous scientific expertise and leadership for valuable clinical research of global, regional, and local application in controlling the epidemic.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Castillo, Blanca E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Chiang Mai University
Chiang Mai
Zip Code
Robertson, K; Oladeji, B; Jiang, H et al. (2018) HIV-1 and TB Co-infection in Multinational Resource Limited Settings: Increased neurological dysfunction. Clin Infect Dis :
Salazar-Austin, N; Kulich, M; Chingono, A et al. (2018) Age-Related Differences in Socio-demographic and Behavioral Determinants of HIV Testing and Counseling in HPTN 043/NIMH Project Accept. AIDS Behav 22:569-579
Shivakoti, Rupak; Ewald, Erin R; Gupte, Nikhil et al. (2018) Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial. Clin Nutr :
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS 32:583-593
Palumbo, Philip J; Fogel, Jessica M; Hudelson, Sarah E et al. (2018) HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. J Acquir Immune Defic Syndr 77:484-491
Cranston, Ross D; Lama, Javier R; Richardson, Barbra A et al. (2017) MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. Clin Infect Dis 64:614-620
Palumbo, Philip J; Wilson, Ethan A; Piwowar-Manning, Estelle et al. (2017) Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. PLoS One 12:e0177281
Greer, Amy E; Ou, San-San; Wilson, Ethan et al. (2017) Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052. J Acquir Immune Defic Syndr 76:388-393
Celum, Connie; Hong, Ting; Cent, Anne et al. (2017) Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J Infect Dis 215:907-910
Currier, Judith S; Britto, Paula; Hoffman, Risa M et al. (2017) Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ? 400 cells/mm3. PLoS One 12:e0176009

Showing the most recent 10 out of 41 publications